Pluri Inc
PLUR
Get informed when a big investor buys or sells
+ FollowMarket Cap$20.86M
Close$
$-2.91
223.3% downside
Current Fair Value
223.3% downsideOvervalued by 223.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $20.86 Million |
|---|---|
| Enterprise Value | $23.88 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.56 |
| Beta | 0.75 |
| Outstanding Shares | 10,054,803 |
Return
| Return on Equity | 143.92% |
|---|---|
| Return on Assets | -171.69% |
| Return on Invested Capital | 165.92% |
Valuation & Multiples
| P/E Ratio | -0.89 |
|---|---|
| PEG | 34.65 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 22.13 |
| Enterprise Value to EBIT | -0.88 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.27 |
| Debt to Equity | -0.35 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$-0.66
Average shareholder expectationRevenue Estimate
$655,000
Average shareholder expectationNext Earnings Call
Expected Date
September 23, 2026
EPS Estimate
$-0.66
Average shareholder expectationRevenue Estimate
$655,000
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.29%▲ 0.01% |
|---|---|
| Total Invested | $91,312▲ 18.32% |
| Investors Holding | 130% |
ESG Score
No data
About Pluri Inc
152 employees
CEO: Zalman Aberman Pluristem Therapeutics Inc. is a leading regenerative medicine company developing novel placenta-based cell therapy product candidates. The Company has reported robust clinical trial data in multiple indications for its patented PLX cell...